Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Accounts Payables: 2016-2024

  • Ascendis Pharma A's Accounts Payables rose 1.24% to $103.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $103.0 million, marking a year-over-year increase of 1.24%. This contributed to the annual value of $104.3 million for FY2024, which is 2.54% up from last year.
  • Ascendis Pharma A's Accounts Payables amounted to $103.0 million in Q4 2024, which was up 1.24% from $101.7 million recorded in Q4 2023.
  • In the past 5 years, Ascendis Pharma A's Accounts Payables registered a high of $103.1 million during Q4 2022, and its lowest value of $26.1 million during Q4 2020.
  • For the 3-year period, Ascendis Pharma A's Accounts Payables averaged around $102.6 million, with its median value being $103.0 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first decreased by 15.05% in 2020, then soared by 160.35% in 2021.
  • Ascendis Pharma A's Accounts Payables (Quarterly) stood at $26.1 million in 2020, then surged by 160.35% to $68.0 million in 2021, then soared by 51.65% to $103.1 million in 2022, then fell by 1.29% to $101.7 million in 2023, then climbed by 1.24% to $103.0 million in 2024.
  • Its last three reported values are $103.0 million in Q4 2024, $101.7 million for Q4 2023, and $103.1 million during Q4 2022.